ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

NVAX Novavax Inc

4.90
0.19 (4.03%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Novavax Inc NASDAQ:NVAX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.19 4.03% 4.90 4.77 5.00 4.94 4.6895 4.84 4,668,267 05:00:08

Novavax to Present at the 15th Annual Needham Healthcare Conference

06/04/2016 9:05pm

GlobeNewswire Inc.


Novavax (NASDAQ:NVAX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Novavax Charts.

Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Stanley C. Erck, President and Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference.

Conference details are as follows:

Date: Wednesday, April 13, 2016Time: 8:40 a.m. U.S. Eastern TimeLocation: Westin Grand Central hotel, New York CityLive webcast: http://wsw.com/webcast/needham76/nvax

The webcast and a replay of the presentation will also be accessible under the “Investors/Events” section of the Novavax website at novavax.com.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for ground-breaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company's website, novavax.com.

Contact: Novavax, Inc.

              Barclay A. Phillips
              SVP, Chief Financial Officer and Treasurer

              Andrea N. Flynn, Ph.D.
              Senior Manager, Investor Relations

              ir@novavax.com
              240-268-2000

              Russo Partners, LLC

              David Schull
              Todd Davenport, Ph.D.

              david.schull@russopartnersllc.com
              todd.davenport@russopartnersllc.com
              212-845-4271

1 Year Novavax Chart

1 Year Novavax Chart

1 Month Novavax Chart

1 Month Novavax Chart

Your Recent History

Delayed Upgrade Clock